Targeted Strategies for Today's Evolving Markets

MissionIR Blog

BiondVax Pharmaceuticals (BVXV) Presents at Rodman & Renshaw Conference

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), an innovative biopharmaceutical company, is developing a universal flu vaccine designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. BiondVax’s go-to-market strategy for its lead candidate, M-001, is to initially obtain regulatory approval for its use as a primer to a pandemic or seasonal vaccine; following the accumulation of enough data, BiondVax will test and gain approval for its use as a universal standalone vaccine. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.